A Clinical Study Of The TACE Combined With RFA Treatment For Advanced Primary Liver Cancer

Objective:The aim of this study is to assessethe clinical efficacy of TACE and RFA on the treatment of primary liver cancer and the influence on the liver function of the TACE and RFA.Materials and Methods:64 patients with oadvanced primary liver cancer were divided into two groups, which were TACE + RFA combination therapy(experimental group) 35 cases, and simple TACE(control group) 29 cases. None patient was treated before. TACE treatment included iodized oil injection over 5-20 ml + MMC4-10 mg + CBP25-100 mg+E-ADM 10-30mg+gelatin sponge particles. The dose was determined by the tumor size and the liver function.The repetition interval of TACE was 3-4 weeks. The treatment was repeated 2-3 times. In combination therapy group, tumor ablation was performed two weeks after TACE. The RFA was guided by ultrasound. The RFA protocol was based on tumor size and shape. A single point was applied in diameter <3 cm lesion, A multi-pin and multi-level overlap processin those lesions of diameter> 3 cm.Results:①Term effect:the difference was statistically significant(P <0.05),the combination therapy group and TACE group efficiency(RR) were 77.14%(27/35) and 51.72%(15/29) respectively.②Tumor shrinkage Study Group 6, 12 months after the total effective rates were 70.0%, 72.4%, 69.6% in the control group was 0.7%, 42.9%, 38.1%. There was no significant differences(P<0.05) in 3 months. Tumor shrink significantly higher(P<0.05) in 6,12-month. PD increased in 6, 12 months, while the study group were significantly higher than the control group(P <0.05 difference).Toxicity: no statistically significant difference(P> 0.05).Conclusion:The combination therapy of TACE + RFA is more effective than the simple one in un-resectable liver cancer. It can effectively prolong the survival complication rate. First of all, there is a synergistic effect of TACE and RFA treatment that can effectively prolong survival and improve the quality of life of patients and restrict the local tumor growth.Secondly, the TACE and RFA do not increase the toxicity. Thirdly, the TACE combined with RFA is better than the single TACE. Combined therapy could effectively restrict tumors, especially in the long-term effectiveness.